1CG fundamentals
An in-depth look to CRISPR THERAPEUTIC operating, investing, and financing activities
1CG free cash flow for Q1 24 is 98.36 M CHF. For 2023, 1CG free cash flow was -227.19 M CHF and operating cash flow was -219.22 M CHF.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CHF
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM